HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Delgado, M. Articles by Ganea, D. Search for Related Content PubMed PubMed Citation Articles by Delgado, M. Articles by Ganea, D.

Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase-Activating Polypeptide Inhibit T Cell-Mediated Cytotoxicity by Inhibiting Fas Ligand Expression¹

Mario Delgado^*, and Doina Ganea^2,*

^* Department of Biological Sciences, Rutgers University, Newark, NJ 07102; and Departamento Biologia Celular, Facultad de Biologia, Universidad Complutense, Madrid, Spain

We reported recently that the neuropeptides vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) protect CD4⁺ T cells against Ag-induced apoptosis by down-regulating the expression of Fas ligand (FasL). Because the cytotoxic activity of CD8⁺ CTLs is mediated through two mechanisms, which involve the perforin/granzyme and the FasL/Fas pathways, in this study we investigated the effects of VIP/PACAP on the generation and activity of allogeneic CTLs, of CD8⁺ T1 and T2 effector cells and of alloreactive peritoneal exudate cytotoxic T cells (PEL) generated in vivo. VIP/PACAP did not affect perforin/granzyme-mediated cytotoxicity, perforin gene expression, or granzyme B enzymatic activity, but drastically inhibited FasL/Fas-mediated cytotoxicity against allogeneic or syngeneic Fas-bearing targets. VIP/PACAP inhibit CTL generation, but not the activity of competent CTLs. The inhibition is associated with a profound down-regulation of FasL expression, and these effects are mediated through both VPAC1 and VPAC2 receptors. VIP/PACAP inhibit the FasL/Fas-mediated cytotoxicity of T1 effectors and do not affect T2 cytotoxicity, which is entirely perforin/granzyme mediated. Similar effects were observed in vivo. Both the FasL/Fas-mediated cytotoxicity and FasL expression of cytotoxic allogeneic PELs generated in vivo in the presence of VIP or PACAP were significantly reduced. We conclude that, similar to their effect on CD4⁺ T cells, the two structurally related neuropeptides inhibit FasL expression in CD8⁺ cytotoxic T cells and the subsequent lysis of Fas-bearing target cells.

This article has been cited by other articles:

				M. Delgado, D. Pozo, and D. Ganea The Significance of Vasoactive Intestinal Peptide in Immunomodulation Pharmacol. Rev., June 1, 2004; 56(2): 249 - 290. [Abstract] [Full Text] [PDF]

				J. Liu, C. S. Schmidt, F. Zhao, A. J. Okragly, A. Glasebrook, N. Fox, E. Galbreath, Q. Zhang, H. Y. Song, S. Na, et al. LIGHT-deficiency impairs CD8+ T cell expansion, but not effector function Int. Immunol., July 1, 2003; 15(7): 861 - 870. [Abstract] [Full Text] [PDF]

				P. Prolo, F. Chiappelli, G. Bernard, M. Fiala, A. Ibarra, M.L. Sartori, A. Dovio, and A. Angeli Neuroendocrine-Immune Surveillance of Osteosarcoma: Emerging Hypothesis J. Dent. Res., June 1, 2003; 82(6): 417 - 421. [Abstract] [Full Text] [PDF]

				D. Ganea and M. Delgado VASOACTIVE INTESTINAL PEPTIDE (VIP) AND PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP) AS MODULATORS OF BOTH INNATE AND ADAPTIVE IMMUNITY Crit. Rev. Oral. Biol. Med., May 1, 2002; 13(3): 229 - 237. [Abstract] [Full Text]

				G. Dorsam and E. J. Goetzl Vasoactive Intestinal Peptide Receptor-1 (VPAC-1) Is a Novel Gene Target of the Hemolymphopoietic Transcription Factor Ikaros J. Biol. Chem., April 12, 2002; 277(16): 13488 - 13493. [Abstract] [Full Text] [PDF]